Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma

Cancer Research

Volumn 72, Issue 7, 2012, Pages 1890-1900

  Pan, Yunbao ^a,c   Zhang, Qingxiu ^c   Tian, Ling ^c   Wang, Xin ^b   Fan, Xiaohang ^a   Zhang, Huizhong ^b   Claret, Francois X ^c,d   Yang, Huiling ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COP9 SIGNALOSOME; JAB1 PROTEIN; PROTEASOME; PROTEIN P27; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING;

ADULT; AGED; CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84859387866     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3472     Document Type: Article

References (36)

1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005;365:2041-54. (Pubitemid 40812341)
2. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, et al. Nasopharyngeal carcinomas: an update. Eur J Cancer 2003;39:2121-35. (Pubitemid 37297736)
3. Ong YK, Heng DM, Chung B, Leong SS, Wee J, FongKW, et al. Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer 2003;39:1535-41. (Pubitemid 36829194)
4. Yip WK, Leong VC, Abdullah MA, Yusoff S, Seow HF. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR, and BAD in nasopharyngeal carcinoma. Oncol Rep 2008;19:319-28. (Pubitemid 351176090)
5. Zheng XK, Chen LH, Wang WJ, Ye F, Liu JB, Li QS, et al. Impact of prolonged fraction delivery times simulating IMRT on cultured nasopharyngeal carcinoma cell killing. Int J Radiat Oncol Biol Phys 2010;78:1541-7.
6. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-7. (Pubitemid 28175745)
7. Lee AW, Yau TK, Wong DH, Chan EW, Yeung RM, Ng WT, et al. Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. Int J Radiat Oncol Biol Phys 2005;63:1331-8. (Pubitemid 41628026)
8. Le QT, Tate D, Koong A, Gibbs IC, Chang SD, Adler JR, et al. Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2003;56:1046-54. (Pubitemid 36794036)
9. Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 2010;42:599-603.
10. Natasya Naili MN, Hasnita CH, Shamim AK, Hasnan J, Fauziah MI, Narazah MY, et al. Chromosomal alterations in Malaysian patients with nasopharyngeal carcinoma analyzed by comparative genomic hybridization. Cancer Genet Cytogenet 2010;203:309-12.
11. Hwang CF, Su CY, Huang SC, Huang CC, Fang FM, Lui CC, et al. Low expression levels of p27 correlate with loco-regional recurrence in nasopharyngeal carcinoma. Cancer Lett 2003;189:231-6.
12. Ko MT, Su CY, Huang SC, Chen CH, Hwang CF. Overexpression of cyclin E messenger ribonucleic acid in nasopharyngeal carcinoma correlates with poor prognosis. J Laryngol Otol 2009;123:1021-6.
13. Mei YP, Zhou JM, Wang Y, Huang H, Deng R, Feng GK, et al. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle 2007;6:1379-85. (Pubitemid 47327973)
14. Wei N, Deng XW. The COP9 signalosome. Annu Rev Cell Dev Biol 2003;19:261-86. (Pubitemid 37487350)
15. Claret FX, Hibi M, Dhut S, Toda T, Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 1996;383:453-7. (Pubitemid 26330837)
16. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 1999;398:160-5.
17. 1-phase progression. Genes Dev 1999;13:1501-12.
18. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
19. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
20. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res 2003;63:2977-81. (Pubitemid 36667172)
21. Rassidakis GZ, Claret FX, Lai R, Zhang Q, Sarris AH, McDonnell TJ, et al. Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clin Cancer Res 2003;9:1121-8. (Pubitemid 36323721)
22. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tai Y, et al. Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res 2001;7:4130-5. (Pubitemid 34044637)
23. Fukumoto A, Ikeda N, Sho M, Tomoda K, Kanehiro H, Hisanaga M, et al. Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic cancer. Oncol Rep 2004;11:277-84.
24. Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P, et al. Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma. Cancer Res 2006;66:8581-9. (Pubitemid 44449172)
25. Berg JP, Zhou Q, Breuhahn K, Schirmacher P, Patil MA, Chen X, et al. Inverse expression of Jun activation domain binding protein 1 and cell cycle inhibitor p27Kip1: influence on proliferation in hepatocellular carcinoma. Hum Pathol 2007;38:1621-7. (Pubitemid 47589084)
26. Ito Y, Yoshida H, Matsuzuka F, Matsuura N, Nakamura Y, Nakamine H, et al. Jun activation domain-binding protein 1 expression in malignant lymphoma of the thyroid: its linkage to degree of malignancy and p27 expression. Anticancer Res 2003;23:4121-5. (Pubitemid 37474908)
27. Shen L, Tsuchida R, Miyauchi J, Saeki M, Honna T, Tsunematsu Y, et al. Differentiation-associated expression and intracellular localization of cyclin-dependent kinase inhibitor p27KIP1 and c-Jun co-activator JAB1 in neuroblastoma. Int J Oncol 2000;17:749-54.
28. Dahinden C, Ingold B, Wild P, Boysen G, Luu VD, Montani M, et al. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 2010;16:88-98.
29. Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, et al. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene 2010;29:6125-37.
30. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4. (Pubitemid 27064711)
31. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 1999;59:3790-4. (Pubitemid 29381888)
32. Singh SP, Lipman J, Goldman H, Ellis FH Jr, Aizenman L, Cangi MG, et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998;58:1730-5. (Pubitemid 28215101)
33. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, et al. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res 1998;58:114-22. (Pubitemid 28027726)
34. Shackleford TJ, Claret FX. JAB1/CSN5: a new player in cell cycle control and cancer. Cell Div 2010;5:26.
35. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74. (Pubitemid 24228301)
36. Supriatno, Harada K, Yoshida H, Sato M. Basic investigation on the development of molecular targeting therapy against cyclin-dependent kinase inhibitor p27Kip1 in head and neck cancer cells. Int J Oncol 2005;27:627-35.